Drug intelligence / Profile preview

LPT-354

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-354 is an improved medical device or drug (IMD) being developed by LitePharmTech as an ophthalmic solution. Currently in the preclinical stage of development, LPT-354 is part of a series of ophthalmic candidates (including LPT-301 and LPT-351 through LPT-354) utilizing the company's IMD platform. In the South Korean regulatory environment, IMD typically refers to Incrementally Modified Drugs, which are formulations that offer improvements in safety, efficacy, or convenience over existing products. The specific active ingredient and therapeutic target for LPT-354 have not been disclosed.

Beyond the preview

Go deeper on LPT-354.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-354.

Explore the full profile